Infant Bacterial Therapeutics (IBT) publicerar nya resultat i British Journal of Gastroenterology som validerar “Sustained Feeding Tolerance” (SFT) som relevant primär endpoint i ‘The Connection Study’
January 24, 2023 11:43 ET
|
Infant Bacterial Therapeutics AB
”The Connection Study” är en randomiserad, dubbelblind multicenterstudie i fas 3 av den probiotiska läkemedelskandidaten IBP-9414. Studien har två oberoende primära endpoints- förekomsten av...
Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’
January 24, 2023 11:43 ET
|
Infant Bacterial Therapeutics AB
The ‘Connection Study’ on the pharmaceutical grade probiotic IBP-9414 has two independent primary endpoints- the incidence of Necrotizing Enterocolitis (NEC) and the time to a strict definition of...
Artikel baserad på Infant Bacterial Therapeutics “Connection Study” publicerad i British Journal of Gastroenterology visar att en dags minskning av tiden till “Sustained Feeding Tolerance (SFT)” korrelerar med klinisk meningsfulla resultat
November 01, 2022 03:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) "Connection Study" består av två oberoende primära endpoints, förekomsten av NEC och tiden tills man når SFT. SFT ett sammansatt effektmått definierat som den...
Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.
November 01, 2022 03:00 ET
|
Infant Bacterial Therapeutics AB
The two independent primary endpoints of the ‘Connection Study’ are the incidence of NEC and the time to SFT. SFT a composite endpoint defined as the first day of tolerating daily enteral feeds of...
NEXEN TIRE releases third annual ESG report with results of its sustainable management performance
September 13, 2022 04:00 ET
|
Nexen Tire
SEOUL, South Korea, Sept. 13, 2022 (GLOBE NEWSWIRE) -- NEXEN TIRE, a leading global tire manufacturer, announced the release of its ESG report for 2021–2022 that contains data on the company’s...
Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari – 30 juni 2022
August 25, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och vi har sett en ökning av rekryteringstakten. Vi har som jag tidigare nämnt arbetat med ett flertal aktiviteter...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
August 25, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates and, as mentioned previously, have been...
Infant Bacterial Therapeutics AB utser Maria Ekdahl till CFO
June 30, 2022 11:00 ET
|
Infant Bacterial Therapeutics AB
Pressmeddelande 30 juni 2022 Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Maria Ekdahl utsetts till Chief Financial Officer (CFO) och tillträder den 19 september 2022. Hon kommer att...
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
June 30, 2022 11:00 ET
|
Infant Bacterial Therapeutics AB
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2022 10:00 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...